IGM Biosciences, Inc. (IGMS)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 143,623 | 499 | 516 | |
| Research and development | 5,863 | 22,337 | 46,142 | |
| Impairment and disposal of long-lived assets | 31,917 | 21,889 | - | |
| General and administrative | 9,581 | 11,049 | 18,761 | |
| Total operating expenses | 47,361 | 55,275 | 64,903 | |
| Income (loss) from operations | 96,262 | -54,776 | -64,387 | |
| Interest income | 1,322 | - | 2,957 | |
| Total other income | 1,322 | - | 2,957 | |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | - | -61,430 | |
| Net income (loss) | 97,584 | -54,776 | -61,430 | |
| Earnings per share, basic, total | 1.59 | -0.86 | -1.01 | |
| Earnings per share, diluted, total | 1.58 | -0.86 | -1.01 | |
| Weighted average number of shares outstanding, basic, total | 61,462,957 | 61,162,762 | 60,657,797 | |
| Weighted average number of shares outstanding, diluted, total | 61,751,283 | 61,162,762 | 60,657,797 | |